J&J woos Merck's Mathai Mammen to helm of pharma R&D, Hait takes over on external innovation
J&J is executing a changeup in the leadership of its multibillion-dollar R&D group.
The pharma giant, which recently signaled plans to expand its drug pipeline — which costs about $7 billion a year to operate (the total R&D budget was $9.1 billion last year)— recruited Merck SVP Mathai Mammen to take Bill Hait’s role as pharma R&D chief, according to a statement out Wednesday night.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.